Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | PCNA | P12004 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354239 | 0.82 | CYP2D6 (0.50) | ALDH1A1SYKCYP2D6CYP2C19 | |
| SCHEMBL12442980 | 0.80 | KDM4E (0.34) | KDM4EMAPK1HIF1APAOXMTNR1A | |
| SCHEMBL8255995 | 0.78 | SYK (0.32) | SYK | |
| SCHEMBL8225884 | 0.78 | SYK (0.32) | SYK | |
| SCHEMBL8225897 | 0.78 | SYK (0.32) | SYK | |
| SCHEMBL4683204 | 0.77 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL2723468 | 0.75 | MEN1 (0.46) | KDM4ESYKCYP2D6 | |
| SCHEMBL2723471 | 0.75 | MEN1 (0.46) | KDM4ESYKCYP2D6 | |
| SCHEMBL13559963 | 0.75 | — | — | |
| SCHEMBL13779167 | 0.74 | MTNR1A (0.39) | KDM4EMAPK1HIF1APAOXMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | KDM4E 3477/4885MAPK1 664/4885HIF1A 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.